'No excuse': ICER determines AstraZeneca's new moneymaker Soliris is vastly overpriced
The ink has barely dried on AstraZeneca’s $39 billion deal to swallow Alexion back in July. But independent drug watchdog ICER has been crunching the numbers, and it decided that the star of the deal — rare disease moneymaker Soliris — is grossly overpriced for the treatment of an uncommon autoimmune disorder.
ICER on Wednesday released its full report examining the cost-effectiveness of Soliris (also known as eculizumab) in an autoimmune disease called myasthenia gravis (MG). In patients with the disorder, antibodies destroy communication between the nerves and muscle, resulting in muscle weakness.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 124,600+ biopharma pros reading Endpoints daily — and it's free.